KalVista Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell KALV and other ETFs, options, and stocks.About KALV
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa.
KALV Key Statistics
KALV News
Analyst Andrew Fein from H.C. Wainwright reiterated a Buy rating on KalVista Pharmaceuticals and keeping the price target at $27.00. Elevate Your Investing Stra...
KalVista Pharmaceuticals, Inc. ( (KALV) ) has released its Q1 earnings. Here is a breakdown of the information KalVista Pharmaceuticals, Inc. presented to its i...
KalVista Pharmaceuticals, Inc. ((KALV)) has held its Q1 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advant...
Analyst ratings
100%
of 10 ratingsMore KALV News
Earnings News KalVista Pharmaceuticals GAAP EPS of -$1.12 misses by $0.17, revenue of $1.43M misses by $0.66M Sep. 11, 2025 7:03 AM ET KalVista Pharmaceuticals,...
KalVista Pharmaceuticals, Inc. KALV will release earnings results for the first quarter before the opening bell on Thursday, Sept. 11. Analysts expect the Camb...
